MERCURNA BV

Their core work

MERCURNA BV is a Dutch biotech SME developing RNA-based medicines, combining nanomedicine delivery technology with mRNA approaches to treat diseases that currently lack effective therapies. Their work spans two distinct therapeutic areas: a kidney-targeted nanomedicine platform designed to stimulate self-repair in chronic kidney disease, and mRNA-based medicines aimed at treating eye conditions. The company leads its own research programs rather than joining larger consortia, positioning itself as an independent drug developer with a focused nucleic acid therapeutics pipeline. Their name itself — merging "medicine," "RNA," and a pharmaceutical frame — signals a company built around RNA as its core technology.

What they specialise in

How they've shifted over time

MERCURNA's H2020 trajectory reveals a company that started with a specific nanomedicine platform for kidney disease and then pivoted the same RNA delivery logic toward a second organ target — the eye. Between 2018 and 2019 their work was grounded in nanomedicine formulation and CKD pathology; by 2019–2021 the emphasis shifted to mRNA molecules specifically, with ophthalmology as the new therapeutic arena. This pattern — same core RNA technology, new indication — suggests they are building a multi-indication pipeline rather than deepening a single disease focus.

MERCURNA is expanding its RNA therapeutics platform across organ systems, moving from kidney to eye disease, which suggests they are developing a modular delivery technology that can be redirected toward multiple high-value indications.

How they like to work

MERCURNA applied to both H2020 projects as sole coordinator under the SME Instrument, a funding pathway designed for individual SMEs rather than research consortia. No consortium partners are recorded, meaning they have operated as a self-contained unit rather than as part of a collaborative network. For potential partners, this signals a company that controls its own IP and research direction — they are more likely to enter partnerships as a technology licensor or in a bilateral collaboration than as a team player in a large multi-partner consortium.

MERCURNA has no recorded consortium partners in the H2020 database, having secured both grants as a standalone SME. Their collaborative footprint within the EU research ecosystem is minimal at this stage.

What sets them apart

MERCURNA occupies a rare niche as a dedicated RNA medicine startup in the Netherlands operating independently of academic spinout structures, with EU-validated feasibility work in two clinically significant areas — chronic kidney disease and ophthalmic disorders — both of which have large unmet therapeutic needs and limited RNA-based treatment options. Their dual-track pipeline (kidney + eye) around a shared RNA delivery platform distinguishes them from single-indication biotech startups. For consortium builders in health or nanomedicine, they bring proprietary platform technology rather than general research capacity.

Highlights from their portfolio

• INSIGHT EU
  One of the earlier EU-funded mRNA medicine projects specifically targeting eye disease, predating the broader mRNA therapeutics wave by several years and demonstrating early platform versatility.
• NanoMed-CKD
  Introduced mCura1, a kidney-targeted nanomedicine with a self-healing mechanism for chronic kidney disease — a disease affecting 10% of the global population with no curative treatment.